Low Levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation

Stroke

Volumn 45, Issue 10, 2014, Pages 3086-3088

  Tran Dinh, Alexy ^a,b   Levoye, Angélique ^a,e   Lambert, Gilles ^f,g   Louedec, Liliane ^a   Journé, Clément ^a   Meilhac, Olivier ^a,d   Amarenco, Pierre ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d Department of Emergency   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f Universite de Nantes   (France)

^g UNIVERSITÉ DE NANTES   (France)

Author keywords

hemorrhage; low density lipoprotein cholesterol; mice; PCSK9 protein; stroke

Indexed keywords

FAT; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KEXIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SUBTILISIN; UNCLASSIFIED DRUG; PCSK9 PROTEIN, MOUSE; SERINE PROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN TISSUE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HEMOGLOBIN DETERMINATION; HEMORRHAGIC TRANSFORMATION; IN VITRO STUDY; LIPID BLOOD LEVEL; MALE; MIDDLE CEREBRAL ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; REPERFUSION INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CELL LINE; CEREBRAL HEMORRHAGE; COMPLICATION; DEFICIENCY; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; RISK FACTOR;

ANIMALS; BLOOD-BRAIN BARRIER; CELL LINE; CEREBRAL HEMORRHAGE; CHOLESTEROL, LDL; ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, KNOCKOUT; PROPROTEIN CONVERTASES; REPERFUSION INJURY; RISK FACTORS; SERINE ENDOPEPTIDASES; STROKE;

EID: 84922481715     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005958     Document Type: Article

References (10)

1. Petrides F, Shearston K, Chatelais M, Guilbaud F, Meilhac O, Lambert G. The promises of PCSK9 inhibition. Curr Opin Lipidol. 2013;24:307-312.
2. Abifadel M, Rabès JP, Devillers M, Munnich A, Erlich D, Junien C, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009;30:520-529.
3. Stein EA, Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014;65:417-431.
4. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology. 2007;68:737-742.
5. Terruso V, D'Amelio M, Di Benedetto N, Lupo I, Saia V, Famoso G, et al. Frequency and determinants for hemorrhagic transformation of cerebral infarction. Neuroepidemiology. 2009;33:261-265.
6. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
7. Lapergue B, Dang BQ, Desilles JP, Ortiz-Munoz G, Delbosc S, Loyau S, et al. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke. Stroke. 2013;44:699-707.
8. Lu A, Clark JF, Broderick JP, Pyne-Geithman GJ, Wagner KR, Khatri P, et al. Mechanical reperfusion is associated with post-ischemic hemorrhage in rat brain. Exp Neurol. 2009;216:407-412.
9. Bao Dang Q, Lapergue B, Tran-Dinh A, Diallo D, Moreno JA, Mazighi M, et al. High-density lipoproteins limit neutrophil-induced damage to the blood-brain barrier in vitro. J Cereb Blood Flow Metab. 2013;33:575-582.
10. Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19:1872-1874.